194 related articles for article (PubMed ID: 38352883)
21. Cross-talk between disulfidptosis and immune check point genes defines the tumor microenvironment for the prediction of prognosis and immunotherapies in glioblastoma.
Zhou Y; Qin X; Hu Q; Qin S; Xu R; Gu K; Lu H
Sci Rep; 2024 Feb; 14(1):3901. PubMed ID: 38365809
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.
Kang K; Li X; Peng Y; Zhou Y
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387
[TBL] [Abstract][Full Text] [Related]
23. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
[TBL] [Abstract][Full Text] [Related]
24. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
25. Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma.
Sun Z; Wang J; Fan Z; Yang Y; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Liu Y; Yang Q; Ma B
J Gene Med; 2024 Jan; 26(1):e3608. PubMed ID: 37897262
[TBL] [Abstract][Full Text] [Related]
26. Identification and validation of disulfidptosis-associated molecular clusters in non-alcoholic fatty liver disease.
Yu X; Guo Z; Fang Z; Yang K; Liu C; Dong Z; Liu C
Front Genet; 2023; 14():1251999. PubMed ID: 37745847
[No Abstract] [Full Text] [Related]
27. Leveraging a disulfidptosis/ferroptosis-based signature to predict the prognosis of lung adenocarcinoma.
Ma X; Deng Z; Li Z; Ma T; Li G; Zhang C; Zhang W; Chang J
Cancer Cell Int; 2023 Nov; 23(1):267. PubMed ID: 37946181
[TBL] [Abstract][Full Text] [Related]
28. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
Zhang HB; Pan JY; Zhu T
Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
[No Abstract] [Full Text] [Related]
29. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
30. Disulfidptosis-related signature predicts prognosis and characterizes the immune microenvironment in hepatocellular carcinoma.
Tang J; Peng X; Xiao D; Liu S; Tao Y; Shu L
Cancer Cell Int; 2024 Jan; 24(1):19. PubMed ID: 38195525
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas.
Liu J; Li G
Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Yang L; Zhang W; Yan Y
Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661
[TBL] [Abstract][Full Text] [Related]
33. Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease.
Luo X; Guo J; Deng H; He Z; Wen Y; Si Z; Li J
Front Immunol; 2024; 15():1386905. PubMed ID: 38812509
[TBL] [Abstract][Full Text] [Related]
34. Identifying molecular subtypes and tumor microenvironment infiltration signatures in kidney renal clear cell carcinoma based on stemness-associated disulfidptosis genes by integrating machine learning, single-cell analyses and experimental validation.
Liu H; Liang X; Tang G; Wang X; Wang Z; Tong L; Mao Q; Ma J; Wu J
Heliyon; 2024 Feb; 10(4):e26094. PubMed ID: 38390172
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
[No Abstract] [Full Text] [Related]
36. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.
Guo Z; Xie Y; Zhang L; Liu S; Jiang W
Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
[TBL] [Abstract][Full Text] [Related]
38. Construction of a novel disulfidptosis-related lncRNAs signature for prognosis prediction and anti-tumor immunity in laryngeal squamous cell carcinoma.
Zhang M; Sun Q; Han Z; Qin X; Gao T; Xu Y; Han S; Zhang Y; Liang Q; Guo Z; Liu J
Heliyon; 2024 May; 10(10):e30877. PubMed ID: 38774325
[TBL] [Abstract][Full Text] [Related]
39. Identification of disulfidptosis-related genes and analysis of immune infiltration characteristics in ischemic strokes.
Qin R; Huang L; Xu W; Qin Q; Liang X; Lai X; Huang X; Xie M; Chen L
Math Biosci Eng; 2023 Oct; 20(10):18939-18959. PubMed ID: 38052584
[TBL] [Abstract][Full Text] [Related]
40. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
